PierianDx Medical Advisor, Catherine Cottrell, Ph.D., FACMG, publishes an article in the Journal of Molecular Diagnostics describing the validation and utility of Washington University GPS’s clinical next generation sequencing assay.
PierianDx Medical Advisor, Catherine Cottrell, Ph.D., FACMG, has published an article in the Journal of Molecular Diagnostics detailing the validation and clinical utility of Washington University Genomic Pathology Services' (GPS) next-generation sequencing (NGS) assay. This study outlines the development and validation process of a comprehensive NGS assay designed to detect a wide array of genetic mutations relevant to cancer diagnosis and treatment.
The article highlights the rigorous validation process undertaken to ensure the assay's accuracy, sensitivity, and specificity. The assay was designed to cover more than 1,200 clinically relevant genes, making it a powerful tool for identifying mutations, copy number variations, and gene fusions that are critical for personalized cancer treatment. The study demonstrates that this NGS assay can reliably detect both common and rare mutations across a variety of cancer types, providing clinicians with valuable information that can guide targeted therapy decisions.
Dr. Cottrell and her team also emphasize the assay's utility in a clinical setting, showcasing its ability to influence treatment decisions and improve patient outcomes. By integrating this NGS assay into routine clinical practice, Washington University GPS has been able to offer more precise and personalized care to cancer patients, highlighting the growing importance of NGS in modern oncology.
The article serves as a significant contribution to the field of molecular diagnostics, underscoring the potential of NGS to revolutionize the way cancer is diagnosed and treated.
Validation of a Next-Generation Sequencing Assay for Clinical Molecular Oncology
Journal of Molecular Diagnostics (Vol. 16, No. 1, January 2014)
